{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":7,"sponsored":0,"items":[{"id":"n_3lxd35inolj4xkaelvea","seq":1357589,"kind":"article","title":"Galderma's Nemluvio shows sustained improvements in moderate-to-severe atopic dermatitis","url":"https://pmlive.com/pharma_news/galdermas-nemluvio-shows-sustained-improvements-in-moderate-to-severe-atopic-dermatitis","published":"2026-10-02T11:56:00Z","seen":"2026-10-02T13:52:51Z","lang":"en","source":{"id":"pmlive.com","name":"pmlive.com","domain":"pmlive.com"},"via":"gdelt-gkg-english","topics":["economy","education","health"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"}],"story":"st_3lxd35inolj4xkaelvea","category":"health","category_p":0.41,"sentiment":"positive","tone":0.07,"political":0.02},{"id":"n_hyi27qv2ln7jat27uzfq","seq":1259120,"kind":"article","title":"Galderma, Switzerland's discreet Botox empire","url":"https://www.lemonde.fr/en/international/article/2026/10/02/galderma-switzerland-s-discreet-botox-empire_6758164_4.html","summary":"The dermatology company's market capitalization has doubled since its initial public offering in 2024. Despite recurring scandals, botulinum toxin injections are expected to rake in $13 billion this year.","published":"2026-10-02T02:49:35Z","seen":"2026-10-02T03:52:02Z","lang":"en","source":{"id":"kite-lemonde-fr-0ab907","name":"lemonde.fr","domain":"lemonde.fr","outlet":{"wikidata":"Q12461","name":"Le Monde","type":"newspaper","country":"FR","designations":["daily newspaper","online newspaper"]}},"via":"kite-lemonde-fr-0ab907","topics":["europe"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"},{"id":"Q39","name":"Switzerland","type":"place"},{"id":"Q4095199","name":"botulinum toxin type A","type":"other"}],"image":"https://img.lemde.fr/2026/03/05/316/0/5634/2817/644/322/60/0/cbb79c6_ftp-1-nppx6smxeu8z-2026-03-05t105549z-494807848-rc2xk6aeizaz-rtrmadp-3-galderma-results-ceo.JPG","story":"st_hyi27qv2ln7jat27uzfq","category":"lifestyle-leisure","category_p":0.25,"category2":"economy-business","sentiment":"neutral","tone":0.22,"political":0.03},{"id":"n_7nneur7kb4cdhj76a4da","seq":876824,"kind":"article","title":"EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis - Iberonews","url":"https://iberonews.com/not_det.php?lang=es&notid=110275","published":"2026-09-30T10:08:22Z","seen":"2026-09-30T10:08:22Z","lang":"en","source":{"id":"iberonews.com","name":"iberonews.com","domain":"iberonews.com"},"via":"gdelt-gkg-english","topics":["science"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.49,"category2":"economy-business","sentiment":"positive","tone":0.34,"political":0.04},{"id":"n_6j52bf6s3cm4wvdbzwiq","seq":865536,"kind":"article","title":"Galderma Reports Three-Year Nemluvio Data In Moderate-to-Severe Atopic Dermatitis","url":"https://www.rttnews.com/3695057/galderma-reports-three-year-nemluvio-data-in-moderate-to-severe-atopic-dermatitis.aspx","published":"2026-09-30T06:00:00Z","seen":"2026-09-30T09:13:21Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","politics"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.39,"sentiment":"neutral","tone":-0.36,"political":0.03},{"id":"n_b3snadvwci5spm3hw4vq","seq":835203,"kind":"article","title":"Galderma's Nemluvio Shows Sustained Three-Year Benefits In Atopic Dermatitis","url":"https://www.rttnews.com/3695051/galderma-s-nemluvio-shows-sustained-three-year-benefits-in-atopic-dermatitis.aspx","published":"2026-09-30T05:44:00Z","seen":"2026-09-30T06:05:48Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","politics"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.49,"sentiment":"positive","tone":0.16,"political":0.02},{"id":"n_jicnankynwl46ghy6ulq","seq":828787,"kind":"article","title":"EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis","url":"https://www.finanznachrichten.de/nachrichten-2026-09/69711730-eadv-2026-galderma-s-new-data-show-sustained-improvements-with-nemluvio-nemolizumab-for-up-to-three-years-in-patients-with-moderate-to-severe-atopi-004.htm","published":"2026-09-30T05:22:42Z","seen":"2026-09-30T05:22:42Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","health","politics","education"],"authors":["Business Wire"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"},{"id":"Q30314619","name":"nemolizumab","type":"other"},{"id":"Q268667","name":"atopic dermatitis","type":"other"}],"story":"st_jicnankynwl46ghy6ulq","category":"health","category_p":0.61,"sentiment":"positive","tone":0.1,"political":0.02},{"id":"n_t6pdyzs5c5s4gs5vuiha","seq":844261,"kind":"article","title":"EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis","url":"https://www.thewhig.com/press-releases/business-wire/eadv-2026-galdermas-new-data-show-sustained-improvements-with-nemluvio-nemolizumab-for-up-to-three-years-in-patients-with-moderate-to-severe-atopic-dermatitis","published":"2026-09-30T05:04:00Z","seen":"2026-09-30T07:14:32Z","lang":"en","source":{"id":"thewhig.com","name":"thewhig.com","domain":"thewhig.com","outlet":{"wikidata":"Q928635","name":"Kingston Whig-Standard","type":"newspaper","country":"CA","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","education","health","politics"],"authors":["Business Wire"],"entities":[{"id":"Q581008","name":"Galderma","type":"org"},{"id":"Q30314619","name":"nemolizumab","type":"other"},{"id":"Q268667","name":"atopic dermatitis","type":"other"}],"story":"st_5srwxlcatjcqhidujepq","category":"health","category_p":0.6,"sentiment":"positive","tone":0.14,"political":0.02}]}